Abstract
CD4+ T helper has an important role in maintain long-term antitumor effect. AJ madu reported that there was a significant decrease between CD4 values before and after chemotherapy. Researchers wanted to investigate the effects of neoadjuvant chemotherapy on CD4+ levels in patients with locally advanced breast cancer at Dr. Mohammad Hoesin Palembang. This study was a non-comparable clinical trial by looking at serum CD4+ levels in locally advanced breast cancer patients before and after neoadjuvant chemotherapy. There are 30 subjects the subject age ranged from 33-66 years with an average of 45 years. 29 patients with marital status (96.7%), 17 patients with contraception history (56.7%), 13 patients with family history of Breast Cancer (43.3%). 23 patients with good chemotherapy response (76.7%) and 7 patients who had poor chemotherapy response (23.3%). Statistical test results using paired t-test showed that there was a significant difference in mean CD4+ count before and after neoadjuvan chemotherapy. At the CD4+ level before chemotherapy 775.55 had a sensitivity of 60% and a specificity of 57% (cut of point). While CD4+ levels after chemotherapy 470.85 with sensitivity of 60% and specificity of 57%. CD4+ pre-chemotherapy examination had a sensitivity score of 60% and a specificity of 57%.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
